Pulmonary Arterial Hypertension - Epidemiology Forecast - 2034

Pulmonary Arterial Hypertension - Epidemiology Forecast - 2034

DelveInsight’s ‘Pulmonary Arterial Hypertension – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of Pulmonary Arterial Hypertension, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Pulmonary Arterial Hypertension Understanding

Pulmonary arterial hypertension (PAH) is one form of a broader condition known as pulmonary hypertension, which is high blood pressure in the lungs. The occlusion of the lung's tiny arteries, which can occur for a number of causes, is the cause of the elevated vascular pressure in pulmonary arterial hypertension.

Severe dyspnea after physical activity, coupled with extreme exhaustion, lassitude, dizziness, and fainting episodes, are the primary symptoms of pulmonary arterial hypertension. Additionally seen are hemoptysis, hypotension, and hoarseness brought on by an enlarged pulmonary artery compressing a nerve in the chest. Advanced phases are marked by cyanosis, syncope, tachypnea, and hypertrophy, which cause the right part of the heart to perform less well and frequently result in right heart failure.

Idiopathic pulmonary arterial hypertension is the most common type and is characterized by constriction of blood vessels in the pulmonary vasculature and high vascular resistance. Restricted flow via pulmonary arteries, as shown in pulmonary arterial hypertension, is thought to be caused primarily by molecular and genetic mechanisms that cause adventitia, endothelial cells, and smooth muscle hypertrophy.

Pulmonary Arterial Hypertension Diagnosis

When diagnosing pulmonary arterial hypertension, transthoracic echocardiography is the most commonly used technique. To identify pulmonary arterial hypertension, further tests such as blood, pulmonary function tests, chest radiography, and electrocardiograms (ECGs) are performed. As our understanding of the disease has grown, efforts are also being made to determine Pulmonary Arterial Hypertension using genetic testing and biomarker-based assay. Another popular test to assess a patient's tolerance for activity is the Six-Minute Walk Test (6MWT).

Continued in the report…..

Pulmonary Arterial Hypertension Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of pulmonary arterial hypertension, total diagnosed prevalent cases of pulmonary arterial hypertension, age-specific diagnosed prevalent cases of pulmonary arterial hypertension, gender-specific diagnosed prevalent cases of pulmonary arterial hypertension, class-specific diagnosed prevalent cases of pulmonary arterial hypertension and subtype-specific diagnosed prevalent cases of pulmonary arterial hypertension in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Pulmonary Arterial Hypertension Detailed Epidemiology Segmentation

According to DelveInsight’s estimates in 2022, the total prevalent cases of pulmonary arterial hypertension in the US was, nearly 51,258 in 2022. The total diagnosed prevalent cases of pulmonary arterial hypertension in the US was approximately 30,755 cases in 2022. These cases are expected to rise during the study period.

In 2022, the diagnosed prevalent cases of pulmonary arterial hypertension in the US varied across different age brackets. The highest number of cases was observed in the >75 age group, totaling around 11,853 cases, while the lowest number of cases was reported in the 18-25 age group, with about 501 cases.

According to DelveInsight’s estimates in 2022, the gender-specific diagnosed prevalent cases of pulmonary arterial hypertension in the US were approximately 23,355 females and 7,400 males.

In 2022, in the class-specific diagnosed prevalent cases of pulmonary arterial hypertension in the US, there were nearly 2,371 cases of class I, 10,878 cases of class II, 15,344 cases of class III, and 2,162 cases of class IV, respectively.

The diagnosed prevalent cases of pulmonary arterial hypertension were categorized into various subtypes based on underlying pathogenesis. In the US, the highest number of cases was reported for idiopathic/heritable pulmonary arterial hypertension with approximately 13,289 cases, while the lowest number was observed in pulmonary veno-occlusive disease, with nearly 163 cases in 2022.

Among EU4 and the UK, Germany accounted for the highest number of pulmonary arterial hypertension-diagnosed cases i.e., approximately 5,059 cases, among EU4 and the UK countries, while Spain accounted for the least with nearly 2,830 cases in 2022.

In 2022, among EU4 and the UK, the highest age-specific diagnosed prevalent cases were in the age group 66-75 years with nearly 3,877 cases and the lowest was in the 18-25 group with nearly 856 cases.

According to DelveInsight estimates, class III accounted for the highest diagnosed prevalent cases of pulmonary arterial hypertension, with nearly 10,255 cases, compared to class I, class II, and class IV with nearly 986, 7,691, and 789 cases in 2022, in EU4 and the UK.

In 2022, the total prevalent cases of pulmonary arterial hypertension in Japan were nearly 3,975, among these 2,385 cases were diagnosed. It is anticipated that these figures will decrease throughout the study period.

Scope of the Report

The report covers a descriptive overview of pulmonary arterial hypertension, explaining its symptoms, pathophysiology, and various diagnostic approaches.

The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The report assesses the disease risk and burden of pulmonary arterial hypertension.

The report helps recognize the growth opportunities in the 7MM concerning the patient population.

The report provides the segmentation of the disease epidemiology for the 7MM, the total prevalent cases of pulmonary arterial hypertension, total diagnosed prevalent cases of pulmonary arterial hypertension, age-specific diagnosed prevalent cases of pulmonary arterial hypertension, gender-specific diagnosed prevalent cases of pulmonary arterial hypertension, class-specific diagnosed prevalent cases of pulmonary arterial hypertension, and the subtype-specific diagnosed prevalent cases of pulmonary arterial hypertension.

Report Highlights

Twelve Years Forecast of Pulmonary Arterial Hypertension

The 7MM Coverage

Total Prevalent Cases of Pulmonary Arterial Hypertension

Total Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension

Age-specific Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension

Gender-specific Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension

Class-specific Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension

Subtype-specific Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension

Key Questions Answered

What are the disease risks and burdens of pulmonary arterial hypertension?

What is the historical pulmonary arterial hypertension patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

What would be the forecasted patient pool of pulmonary arterial hypertension at the 7MM level?

What growth opportunities will be across the 7MM concerning the patient population with pulmonary arterial hypertension?

Which country would have the highest diagnosed prevalent population of pulmonary arterial hypertension among the countries mentioned above during the forecast period (2023–2034)?

At what CAGR is the population expected to grow across the 7MM during the forecast period (2023–2034)?

Reasons to Buy

The Pulmonary Arterial Hypertension report will allow the user to:

Develop business strategies by understanding the trends shaping and driving the 7MM Pulmonary arterial hypertension epidemiology forecast.

The pulmonary arterial hypertension epidemiology report and model were written and developed by Master’s and PhD-level epidemiologists.

The pulmonary arterial hypertension epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 12-year forecast period using reputable sources.

Key Assessments

Patient Segmentation

Disease Risk and Burden

Risk of Disease by Segmentation

Factors Driving Growth in a Specific Patient Population

Geographies Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034